The VESALIUS-CV trial (NCT03872401) has proved its long-term efficacy in these patients after meeting both its primary ...

Amgen received a label expansion from the FDA in August 2025, with the VESALIUS-CV data supporting this decision.

Findings from the Phase III VESALIUS-CV study reinforce the cholesterol-lowering benefit of Repatha in high-risk patients ...

In a first-of-its-kind finding, Amgen’s PCSK9 drug protected heart health when tested as a “primary prevention” therapy, ...

Amgen’s phase 3 VESALIUS-CV trial meets primary endpoints in a cardiovascular primary prevention study of 12,000 patients: Thousand Oaks, California Saturday, October 4, 2025, 1 ...

Amgen's late-stage study of human monoclonal antibody Repatha hit its dual primary targets, demonstrating it significantly reduced the risk of major adverse cardiovascular events in individuals ...

The 12,000-patient trial of the PCSK9 inhibitor met its primary endpoints in high-risk individuals with no prior CV events.

Repatha (evolocumab) is an injectable medicine that helps lower levels of low-density lipoprotein cholesterol (LDL), often called “bad” cholesterol. Approved in 2015, Repatha can now be used in adults ...

The FDA has expanded approval of Amgen’s PCSK9 inhibitor Repatha (evolocumab), permitting use in adults at increased risk of major adverse cardiovascular events due to uncontrolled LDL cholesterol, ...

Amgen said yesterday that its cholesterol-lowering injection Repatha cut the risk of a composite of heart disease death, ...

The FDA approved another generic version of the mifepristone abortion pill, a regulatory formality that triggered pushback ...